DEA Schedules Three Fentanyl Variants for Permanent Ban
Published Date: 6/10/2025
Proposed Rule
Summary
The DEA wants to officially put three fentanyl-related drugs into Schedule I, making their control permanent. This affects anyone who makes, sells, studies, or owns these substances, with strict rules and penalties kicking in. The change builds on temporary rules set to expire in September 2025, so the clock’s ticking to lock this down for good!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Three Fentanyl-Related Drugs Moved to Schedule I
The DEA proposes to place three specific fentanyl-related substances into Schedule I of the Controlled Substances Act, making their control permanent if the rule is finalized. This action continues temporary scheduling that traces to the February 6, 2018 order and extensions (including the Temporary Reauthorization Act of February 6, 2020) and follows the most recent extension on March 15, 2025 that lasts until September 30, 2025.
Handlers Face Schedule I Sanctions and Controls
If finalized, the rule would make permanent the regulatory controls and administrative, civil, and criminal sanctions that apply to Schedule I substances for any person who handles or proposes to handle these three substances. The listed handling activities explicitly include manufacture, distribution, import, export, engaging in research, conducting instructional activities or chemical analysis, and possession.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-10294 — Endangered and Threatened Wildlife and Plants; Two Species Not Warranted for Listing as Endangered or Threatened Species
The U.S. Fish and Wildlife Service decided that the cannulate cave isopod and Dry Fork Valley cave beetle don’t need to be listed as endangered or threatened right now. This means no new protections or costs will happen for these species at this time. But, the public can still share new info anytime to help keep an eye on them.
Next: 2025-10422 — Amendment of Class D and Class E5 Airspace; Revocation of Class E4 Airspace Dover, DE
Dover Air Force Base is getting a fresh airspace makeover to keep flights safe and smooth. The rules for different airspace zones around Dover are changing to better fit how planes actually fly there. These updates won’t cost anyone extra and will kick in once finalized.